Literature DB >> 20602148

Non-enhancing relapse of a primary CNS lymphoma with multiple diffusion-restricted lesions.

Lars Fischer1, Arend Koch, Uwe Schlegel, Hans-Christian Koch, Rüdiger Wenzel, Nicolas Schröder, Eckhard Thiel, Agnieszka Korfel.   

Abstract

Primary CNS lymphoma (PCNSL) and its variant primary intraocular lymphoma (PIOL) are rare forms of extranodal non-Hodgkin's lymphoma confined to the CNS including the retina and the optical nerve; histologically, most cases are diffuse large B cell lymphomas. PCNSL in immunocompetent patients display typical radiological features on MRI, i.e. intensely and homogeneously enhancing lesions with moderate edema. Here, we report a 52-year-old male with a history of a PIOL and two consecutive intracerebral relapses who presented with dysarthria, dysphagia, and gait ataxia. Gadolinium-enhanced T1 scans were unremarkable but multiple lesions with restricted water diffusivity were seen on diffusion-weighted imaging. Relapse of his PCNSL was secured histologically only on autopsy. The possible etiology of the diffusion-restricted lesions is discussed.

Entities:  

Mesh:

Year:  2010        PMID: 20602148     DOI: 10.1007/s11060-010-0287-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  18 in total

1.  Change of brain MRI findings in a patient with intravascular malignant lymphomatosis.

Authors:  M Iijima; A Fujita; M Uchigata; H Katoo
Journal:  Eur J Neurol       Date:  2007-05       Impact factor: 6.089

2.  Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting.

Authors:  Maurilio Ponzoni; Andrés J M Ferreri; Elías Campo; Fabio Facchetti; Luca Mazzucchelli; Tadashi Yoshino; Takuhei Murase; Stefano A Pileri; Claudio Doglioni; Emanuele Zucca; Franco Cavalli; Shigeo Nakamura
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

Review 3.  Cerebral MR imaging in intravascular lymphomatosis.

Authors:  R L Williams; C C Meltzer; J G Smirniotopoulos; M B Fukui; M Inman
Journal:  AJNR Am J Neuroradiol       Date:  1998-03       Impact factor: 3.825

4.  Rapidly progressive dementia caused by nonenhancing primary lymphoma of the central nervous system.

Authors:  B A Carlson
Journal:  AJNR Am J Neuroradiol       Date:  1996-10       Impact factor: 3.825

5.  Cerebral lymphoma presenting as a leukoencephalopathy.

Authors:  L Ayuso-Peralta; M Ortí-Pareja; M Zurdo-Hernández; F J Jiménez-Jiménez; J Tejeiro-Martínez; J R Ricoy; A de la Lama; A I Bernardo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-08       Impact factor: 10.154

6.  Cerebral lymphoma presenting as a nonenhancing lesion on computed tomographic/magnetic resonance scan.

Authors:  L M DeAngelis
Journal:  Ann Neurol       Date:  1993-03       Impact factor: 10.422

Review 7.  Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study.

Authors:  Rose Lai; Lauren E Abrey; Marc K Rosenblum; Lisa M DeAngelis
Journal:  Neurology       Date:  2004-02-10       Impact factor: 9.910

Review 8.  Intravascular B-cell lymphoma: report of two cases with different clinical presentation but rapid central nervous system involvement.

Authors:  G Anghel; G Petrinato; A Severino; D Remotti; L Insabato; A De Renzo; B Rotoli; I Majolino
Journal:  Leuk Lymphoma       Date:  2003-08

9.  Diagnosis and management of primary intraocular lymphoma: an update.

Authors:  Kristoph Jahnke; Eckhard Thiel; Lauren E Abrey; Edward A Neuwelt; Agnieszka Korfel
Journal:  Clin Ophthalmol       Date:  2007-09

10.  Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma.

Authors:  R F Barajas; J L Rubenstein; J S Chang; J Hwang; S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2009-09-03       Impact factor: 4.966

View more
  7 in total

1.  The challenge of adequate imaging surveillance in primary central nervous system lymphoma.

Authors:  Uwe Schlegel; Agnieszka Korfel
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

Review 2.  The Challenge of Primary Central Nervous System Lymphoma.

Authors:  Julia Carnevale; James L Rubenstein
Journal:  Hematol Oncol Clin North Am       Date:  2016-12       Impact factor: 3.722

3.  Clinicoradiological changes of brain NK/T cell lymphoma manifesting pure akinesia: a case report.

Authors:  Susumu Ishihara; Osamu Kano; Ken Ikeda; Reiko Shimokawa; Kiyokazu Kawabe; Yasuo Iwasaki
Journal:  BMC Neurol       Date:  2011-11-02       Impact factor: 2.474

4.  Modern techniques of magnetic resonance in the evaluation of primary central nervous system lymphoma: contributions to the diagnosis and differential diagnosis.

Authors:  Antonio José da Rocha; Bruno Vasconcelos Sobreira Guedes; Talita Maira Bueno da Silveira da Rocha; Antonio Carlos Martins Maia Junior; Carlos Sérgio Chiattone
Journal:  Rev Bras Hematol Hemoter       Date:  2015-12-31

5.  The clinical heterogeneity of entirely nonenhancing CNS lymphoma: a case series.

Authors:  Stephen G Bowden; Daniel N Munger; Jaclyn Thiessen; S Cody Schoettler Woll; Seunggu J Han; Edward A Neuwelt; Ramon F Barajas; Prakash Ambady
Journal:  CNS Oncol       Date:  2020-12-16

6.  Primary central nervous system lymphoma: advances in MRI and PET imaging.

Authors:  Prakash Ambady; Leland S Hu; Letterio S Politi; Nicoletta Anzalone; Ramon F Barajas
Journal:  Ann Lymphoma       Date:  2021-09-30

7.  Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).

Authors:  Ramon F Barajas; Letterio S Politi; Nicoletta Anzalone; Heiko Schöder; Christopher P Fox; Jerrold L Boxerman; Timothy J Kaufmann; C Chad Quarles; Benjamin M Ellingson; Dorothee Auer; Ovidiu C Andronesi; Andres J M Ferreri; Maciej M Mrugala; Christian Grommes; Edward A Neuwelt; Prakash Ambady; James L Rubenstein; Gerald Illerhaus; Motoo Nagane; Tracy T Batchelor; Leland S Hu
Journal:  Neuro Oncol       Date:  2021-07-01       Impact factor: 12.300

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.